JCRRF:NYE-

| Drug Manufacturers - General |

Last Closing

USD 4.57

Change

0.00 (0.00)%

Market Cap

N/A

Volume

250.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-03 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
LLY Eli Lilly and Company

-5.52 (-0.62%)

USD 832.38B
JNJ Johnson & Johnson

-0.67 (-0.42%)

USD 391.85B
ABBV AbbVie Inc

-1.37 (-0.70%)

USD 347.65B
PFE Pfizer Inc

-0.27 (-0.94%)

USD 166.09B
BMY Bristol-Myers Squibb Company

+0.44 (+0.82%)

USD 109.89B
OGN Organon & Co

-0.32 (-1.72%)

USD 4.94B
GSK GlaxoSmithKline PLC ADR

-1.08 (-2.74%)

N/A
MRK Merck & Company Inc

-1.90 (-1.70%)

N/A
NVS Novartis AG ADR

-0.70 (-0.61%)

N/A

ETFs Containing JCRRF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -49.45% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.45% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -49.45% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.45% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike